Nature Communications (Sep 2021)
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
- S. Taavitsainen,
- N. Engedal,
- S. Cao,
- F. Handle,
- A. Erickson,
- S. Prekovic,
- D. Wetterskog,
- T. Tolonen,
- E. M. Vuorinen,
- A. Kiviaho,
- R. Nätkin,
- T. Häkkinen,
- W. Devlies,
- S. Henttinen,
- R. Kaarijärvi,
- M. Lahnalampi,
- H. Kaljunen,
- K. Nowakowska,
- H. Syvälä,
- M. Bläuer,
- P. Cremaschi,
- F. Claessens,
- T. Visakorpi,
- T. L. J. Tammela,
- T. Murtola,
- K. J. Granberg,
- A. D. Lamb,
- K. Ketola,
- I. G. Mills,
- G. Attard,
- W. Wang,
- M. Nykter,
- A. Urbanucci
Affiliations
- S. Taavitsainen
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- N. Engedal
- Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital
- S. Cao
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
- F. Handle
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven
- A. Erickson
- Nuffield Department of Surgical Sciences, University of Oxford
- S. Prekovic
- Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute
- D. Wetterskog
- University College London Cancer Institute
- T. Tolonen
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- E. M. Vuorinen
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- A. Kiviaho
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- R. Nätkin
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- T. Häkkinen
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- W. Devlies
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven
- S. Henttinen
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- R. Kaarijärvi
- Institute of Biomedicine, University of Eastern Finland
- M. Lahnalampi
- Institute of Biomedicine, University of Eastern Finland
- H. Kaljunen
- Institute of Biomedicine, University of Eastern Finland
- K. Nowakowska
- University College London Cancer Institute
- H. Syvälä
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- M. Bläuer
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- P. Cremaschi
- University College London Cancer Institute
- F. Claessens
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven
- T. Visakorpi
- Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- T. L. J. Tammela
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- T. Murtola
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- K. J. Granberg
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- A. D. Lamb
- Nuffield Department of Surgical Sciences, University of Oxford
- K. Ketola
- Institute of Biomedicine, University of Eastern Finland
- I. G. Mills
- Nuffield Department of Surgical Sciences, University of Oxford
- G. Attard
- University College London Cancer Institute
- W. Wang
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
- M. Nykter
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center
- A. Urbanucci
- Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital
- DOI
- https://doi.org/10.1038/s41467-021-25624-1
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 16
Abstract
Identifying the molecular mechanisms of response to systemic therapy in prostate cancer remains crucial. Here, the authors apply single cell-ATAC and RNAseq to models of early treatment response and resistance to enzalutamide and identify chromatin and gene expression patterns that can predict treatment response.
